Press Releases

Biophytis Reports 2020 Full Year Results

Biophytis Announces Expansion of Patient Recruitment for Part 2 of the Phase 2-3 COVA Trial (“COVA Study”) following Regulatory Authorities approvals in France and Belgium

Biophytis Announces Closing of ADS Offering on Nasdaq Capital Market

Biophytis Announces Pricing of $20.1 Million U.S. Initial Public Offering of American Depositary Shares and Approval to List on Nasdaq Capital Market

Biophytis Announces Temporary Trading Halt of its Shares and Share Warrants on Euronext Growth

Biophytis Announces Trading Resumption of its Ordinary Shares and Share Warrants on Euronext

Biophytis Announces the Start of Patient Recruitment in Brazil and the USA for Part 2 of the Phase 2-3 COVA Trial (“COVA Study”)

Biophytis Announces the Launch of its Proposed Public Offering and Nasdaq Listing

Biophytis Announces Public Filing of a Registration Statement for Proposed Initial Public Offering in the United-States

Biophytis receives DMC recommendation for starting recruitment for Part 2 of its Phase 2-3 COVA study in COVID-19